TITLE

Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study

AUTHOR(S)
Miner Jr., Philip; Katz, Philip O.; Chen, Yusong; Sostek, Mark
PUB. DATE
December 2003
SOURCE
American Journal of Gastroenterology;Dec2003, Vol. 98 Issue 12, p2616
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES: Proton pump inhibitors owe their clinical efficacy to their ability to suppress gastric acid production. The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. METHODS: This randomized, open-label, comparative five-way crossover study evaluated the 24-h intragastric pH profile of oral esomeprazole 40 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg once daily in 34 Helicobacter pylon-negative patients aged 18-60 yr with symptoms of gastroesophageal reflux disease. Patients were randomly assigned to one of five treatment sequences and study drug was taken on 5 consecutive mornings 30 minutes prior to a standardized breakfast. A washout period of at least 10 days separated each treatment phase. RESULTS: Thirty-four patients provided evaluable data for all five comparators. The mean number of hours of evaluable pH data was ≥23.75 hours. On day 5, intragastric pH was maintained above 4.0 for a mean of 14.0 h with esomeprazole, 12.1 h with rabeprazole, 11.8 h with omeprazole, 11.5 h with lansoprazole, and 10.1 h with pantoprazole (p ≤ 0.00 1 for differences between esomeprazole and all other comparators). Esomeprazole also provided a significantly higher percentage of patients with an intragastric pH greater than 4.0 for more than 12 h relative to the other proton pump inhibitors (p < 0.05). The frequency of adverse events was similar between treatment groups. CONCLUSIONS: Esomeprazole at the standard dose of 40 mg once daily provided more effective control of gastric acid at steady state than standard doses of lansoprazole, omeprazole, pantoprazole, and rabeprazole in patients with symptoms of gastroesophageal reflux disease.
ACCESSION #
15182436

 

Related Articles

  • Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Röhss, Kerstin; Lind, Tore; Wilder-Smith, Clive // European Journal of Clinical Pharmacology;Oct2004, Vol. 60 Issue 8, p531 

    Objective: To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastrooesophageal reflux disorder (GERD). Methods:...

  • Long-term PPI therapy safe.  // Reactions Weekly;May2015, Vol. 1553 Issue 1, p7 

    The article focuses on a study which shows that long-term treatment with the proton pump inhibitors omeprazole and esomeprazole is not linked with any safety concern.

  • The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits. Salim Bastaki; Irwin Chandranath; Jaipaul Singh // Molecular & Cellular Biochemistry;Feb2008, Vol. 309 Issue 1/2, p167 

    Abstract   Proton pump inhibitors (PPIs) are widely used to treat hyperacid secretion and stomach ulcers. The study investigated the anti-secretory and anti-ulcer effects of esomeprazole, the S-isomer of omeprazole on dimaprit, histamine and dibutyryl adenosine 3, 5 cyclic...

  • COMPARISON OF SINGLE DOSE OF OMEPERPRAZOLE (20MG) VERSUS ESOMEPRAZOLE (40MG) ON GASTRIC ACIDITY. NAZEER, TAHIR; AKHTAR, NAILA; YOUNAS, MUHAMMAD; TAHIR, AMNA; AKHTAR BUTT, TANVEER; AZAM, MUHAMMAD // Biomedica;Apr-Jun2014, Vol. 30 Issue 2, p106 

    Objective: The objective of this study was to evaluate and compare the effectiveness of single dose of omeprazole 20mg and esomeprazole 40mg on stomach pH. Material and Methods: In this study 50 patients, of ASA class p1 and p2 status, of age 15 to 60 years and body mass index (BMI) 20 to 35...

  • Intravenous Esomeprazole: A Viewpoint by Peter Bytzer. Bytzer, Peter // Drugs;2004, Vol. 64 Issue 8, p883 

    The intravenous proton pump inhibitor esomeprazole is effective in treating gastroesophageal reflux disease by controlling gastric acid and increasing intragastric pH levels. It has a slower metabolic clearance and longer intragastric pH control. Intravenous esomeprazole is well-tolerated. Its...

  • Acid Reflux Detection and Symptom-Reflux Association Using 4-Day Wireless pH Recording Combining 48-Hour Periods Off and On PPI Therapy. Garrean, Carol P.; Qing Zhang; Gonsalves, Nirmala; Hirano, Ikuo // American Journal of Gastroenterology;Jul2008, Vol. 103 Issue 7, p1631 

    OBJECTIVES: Studies have shown that extended pH recording improves the sensitivity of esophageal pH monitoring. Controversy exists as to whether pH studies are optimally done off or on proton pump inhibitor (PPI) therapy. The aim of this study was to incorporate periods both off and on PPI...

  • Impact of Acid Suppression on Upper Gastrointestinal pH and Motility. Michalek, Whitney; Semler, John; Kuo, Braden // Digestive Diseases & Sciences;Jun2011, Vol. 56 Issue 6, p1735 

    Background: Proton pump inhibitors (PPIs), widely prescribed to patients with upper gastrointestinal symptoms, alter intragastric pH, and may affect upper gastrointestinal transit and motility parameters in addition to affecting the ability to determine Wireless Motility Capsule (WMC) gastric...

  • Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Tan, Antoinette; Gibbon, Darlene; Stein, Mark; Lindquist, Diana; Edenfield, Jeffery; Martin, Julie; Gregory, Charles; Suttle, A.; Tada, Hiroomi; Botbyl, Jeffrey; Stephenson, Joseph // Cancer Chemotherapy & Pharmacology;Jun2013, Vol. 71 Issue 6, p1635 

    Purpose: The metabolism of pazopanib is primarily mediated by CYP3A4. The solubility of pazopanib is pH-dependent, and an elevated gastric pH may decrease its bioavailability. This study evaluated the effect of a potent CYP3A4 inhibitor, ketoconazole, and the proton pump inhibitor esomeprazole...

  • Labeling of omeprazole with technetium-99 m for diagnosis of stomach. Sanad, M. // Radiochemistry;Nov2013, Vol. 55 Issue 6, p605 

    Omeprazole, a proton pump inhibitor, was labeled with Tc to obtain Tc-omeprazole in ∼96% yield in basic media. The optimum conditions were as follows: pH 9, 50 μg of SnCl·2HO, 30 min, and 3 mg of the substrate. Tc-omeprazole was stable for 6 h. Intravenous biodistribution of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics